Last reviewed · How we verify
NCT04223466
Video-assisted Thoracoscopic Thymectomy Versus Subxiphoid Procedure
NA trial testing Subxiphoid surgery procedure in Thymectomy in 100 participants. Currently enrolling.
31 December 2024
Quick facts
| Lead sponsor | The Second Hospital of Shandong University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 7 January 2020 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Subxiphoid surgery procedure
- VATS surgery procedure
Conditions studied
- Thymectomy — all drugs for Thymectomy →
Sponsor
The Second Hospital of Shandong University
Who can join
Adults 20 to 80, any sex, with Thymectomy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Surgerys used in thymectomy for myasthenia gravis and anterior mediastinal tumours have become much less invasive in recent years. In our study, the surgical technique which resected the thymus below the xiphoid process and the technique which was regarded as conventional video- assisted thoracoscopic surgery (VATS) thymectomy was compared.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04223466
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Thymectomy
Currently open trials in the same condition.
- NCT07019857 — Impact of Thymectomy on Immunity in Infants After Cardiac Surgery · NA · recruiting
- NCT06545409 — Serratus Posterior Superior Intercostal Plane Block in Robotic-Assisted Thymectomy · NA · recruiting
Other The Second Hospital of Shandong University trials
Trials by the same sponsor.
- NCT07430579 — Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma · NA · recruiting
- NCT06337968 — CPB for Arthroscopic Hip Surgery · NA · not yet recruiting
- NCT06604091 — Cohort Profile：The Shandong Adenomyosis Cohort of Population Undergoing Reproductive Technology (SAart) · active not recruiting
- NCT06574958 — Clinical Study of CD38\CS1 Chimeric Antigen Receptor T Cells in the Treatment of Refractory/Recurrent Multiple Myeloma · EARLY_PHASE1 · active not recruiting
- NCT06572956 — Clinical Study on the Safety and Efficacy of CAR-T/CAR-NK Cells in the Treatment of Recurrent Refractory or Unresectable · EARLY_PHASE1 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04223466 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Second Hospital of Shandong University
- Last refreshed: 16 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04223466.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing